Strategic outlook GLP-1s for neurodegenerative disease By Dubai Future Foundation The repurposing of GLP-1RAs for neurodegenerative diseases could catalyse a significant shift in the approach to conditions that have long defined late-life decline. As early- stage research explores the potential of these medications for Alzheimer’s and Parkinson’s disease60,61 – affecting nearly 50 million people globally62,63 – their future impact, if validated, could extend beyond clinical outcomes to influence approaches to healthcare delivery, eldercare and societal expectations of ageing. Over the next decade, healthcare delivery systems could begin a meaningful transition towards earlier intervention and disease modification rather than symptom management alone. This evolution could gradually reshape eldercare infrastructure, potentially reducing demand for intensive memory care while creating new care models focused on maintaining function and independence. Healthcare economics could shift as resources reallocate from late-stage care towards prevention and early intervention, potentially improving outcomes while creating new value pathways. The societal impact could be substantial. For patients in early disease stages, even modest delays in progression could translate to additional years of independence and family engagement. If future treatments prove effective in slowing disease progression, this could ease caregiving demands and potentially support greater workforce participation and financial stability for caregivers – who are often women. This may also help older adults remain active and engaged for longer, potentially supporting social continuity and intergenerational connection within communities. Supply chains for this emerging class of drugs are under pressure as demand grows.64,65 Several major pharmaceutical firms have announced large-scale investments aimed at expanding manufacturing capacity – reflecting interest in the potential of GLP-1 therapies and the significant innovation required to meet evolving production needs. Affordability remains a key challenge. With high costs and limited reimbursement in many settings,66,67 GLP-1RAs may present immediate cost tensions despite potential long-term savings in care needs.68 This raises important questions around pricing models that better balance immediate expenses against future benefits, potentially accelerating broader reforms in how healthcare systems value preventive interventions. Given the promising but mixed results from recent clinical trials,69 GLP-1RAs are being explored as a potential component of future therapeutic strategies – pending further clinical validation. Complementary approaches like GIP (glucose-dependent insulinotropic polypeptide) receptor agonists70 are also under investigation, contributing to a potentially more personalized and stage-specific therapeutic landscape as clinical understanding evolves. The potential of GLP-1RAs is currently being explored for their role in shifting the treatment approach to neurodegenerative diseases – from symptom management towards possible disease modification. If future research supports this direction, it could influence how healthcare systems and societies approach ageing and cognitive health, with broader implications for care models and community support structures. Related DFF megatrends: Future Humanity and Advanced Health and Nutrition71 Top 10 Emerging Technologies of 2025 23